| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 60 | 2024 | 804 | 10.360 |
Why?
|
| Brain Neoplasms | 53 | 2025 | 1235 | 6.820 |
Why?
|
| Uterine Cervical Neoplasms | 18 | 2025 | 238 | 4.680 |
Why?
|
| Glioma | 28 | 2021 | 496 | 4.330 |
Why?
|
| Papillomavirus Infections | 19 | 2025 | 284 | 4.290 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2025 | 2586 | 3.270 |
Why?
|
| Uterine Cervical Dysplasia | 9 | 2023 | 30 | 3.120 |
Why?
|
| Medulloblastoma | 16 | 2024 | 338 | 3.000 |
Why?
|
| Central Nervous System Neoplasms | 10 | 2023 | 194 | 2.910 |
Why?
|
| Child | 170 | 2025 | 24237 | 2.870 |
Why?
|
| Cerebellar Neoplasms | 14 | 2024 | 282 | 2.720 |
Why?
|
| Sarcoma, Kaposi | 12 | 2023 | 120 | 2.700 |
Why?
|
| Neoplasms | 21 | 2024 | 2758 | 2.640 |
Why?
|
| HIV Infections | 19 | 2023 | 1874 | 2.270 |
Why?
|
| Genetic Predisposition to Disease | 37 | 2024 | 3084 | 2.190 |
Why?
|
| Humans | 284 | 2025 | 123171 | 2.120 |
Why?
|
| Female | 196 | 2025 | 65500 | 2.100 |
Why?
|
| Child, Preschool | 101 | 2025 | 13887 | 2.080 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2024 | 532 | 2.070 |
Why?
|
| Adolescent | 109 | 2025 | 19103 | 1.970 |
Why?
|
| Genome-Wide Association Study | 20 | 2025 | 1641 | 1.940 |
Why?
|
| Case-Control Studies | 49 | 2024 | 3249 | 1.910 |
Why?
|
| Risk Factors | 72 | 2024 | 10010 | 1.840 |
Why?
|
| Male | 167 | 2025 | 60084 | 1.830 |
Why?
|
| Methotrexate | 10 | 2024 | 341 | 1.790 |
Why?
|
| DNA, Viral | 12 | 2023 | 478 | 1.730 |
Why?
|
| Papillomaviridae | 11 | 2023 | 139 | 1.710 |
Why?
|
| Leukemia | 12 | 2023 | 375 | 1.560 |
Why?
|
| Infant | 72 | 2025 | 12348 | 1.540 |
Why?
|
| Adult | 95 | 2025 | 29062 | 1.530 |
Why?
|
| Environmental Exposure | 7 | 2024 | 217 | 1.490 |
Why?
|
| SEER Program | 13 | 2022 | 194 | 1.490 |
Why?
|
| Registries | 17 | 2025 | 1392 | 1.490 |
Why?
|
| Human papillomavirus 16 | 8 | 2025 | 47 | 1.480 |
Why?
|
| Genotype | 28 | 2024 | 2542 | 1.410 |
Why?
|
| Particulate Matter | 3 | 2024 | 69 | 1.360 |
Why?
|
| Texas | 34 | 2024 | 3555 | 1.360 |
Why?
|
| DNA Methylation | 8 | 2025 | 987 | 1.330 |
Why?
|
| Young Adult | 52 | 2025 | 8863 | 1.290 |
Why?
|
| Air Pollutants | 7 | 2019 | 101 | 1.280 |
Why?
|
| Residence Characteristics | 8 | 2024 | 269 | 1.280 |
Why?
|
| Rhabdomyosarcoma | 8 | 2025 | 200 | 1.260 |
Why?
|
| Glioblastoma | 6 | 2025 | 334 | 1.250 |
Why?
|
| Roseolovirus Infections | 3 | 2013 | 33 | 1.220 |
Why?
|
| Herpesvirus 6, Human | 3 | 2013 | 58 | 1.200 |
Why?
|
| Hypersensitivity | 5 | 2022 | 182 | 1.170 |
Why?
|
| Genetic Variation | 7 | 2024 | 1480 | 1.090 |
Why?
|
| Craniospinal Irradiation | 3 | 2024 | 58 | 1.070 |
Why?
|
| Papillomavirus Vaccines | 3 | 2017 | 93 | 1.050 |
Why?
|
| Cancer Survivors | 6 | 2023 | 199 | 1.050 |
Why?
|
| Prognosis | 31 | 2025 | 4507 | 1.050 |
Why?
|
| Hydroxyurea | 2 | 2024 | 81 | 1.040 |
Why?
|
| Middle Aged | 57 | 2025 | 25994 | 1.030 |
Why?
|
| Health Status Disparities | 5 | 2021 | 219 | 1.010 |
Why?
|
| Metabolomics | 4 | 2021 | 409 | 1.010 |
Why?
|
| Folic Acid | 4 | 2024 | 292 | 1.000 |
Why?
|
| Anemia, Sickle Cell | 3 | 2024 | 334 | 1.000 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2024 | 226 | 0.980 |
Why?
|
| Human papillomavirus 18 | 4 | 2025 | 7 | 0.970 |
Why?
|
| Venous Thromboembolism | 3 | 2024 | 161 | 0.970 |
Why?
|
| Ependymoma | 4 | 2023 | 133 | 0.940 |
Why?
|
| Prevalence | 13 | 2024 | 2406 | 0.930 |
Why?
|
| Epoxide Hydrolases | 3 | 2013 | 33 | 0.920 |
Why?
|
| Biomarkers, Tumor | 10 | 2025 | 1430 | 0.900 |
Why?
|
| Incidence | 25 | 2025 | 3047 | 0.900 |
Why?
|
| Vehicle Emissions | 4 | 2019 | 19 | 0.870 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 178 | 0.870 |
Why?
|
| Endogenous Retroviruses | 1 | 2023 | 17 | 0.860 |
Why?
|
| Neuroectodermal Tumors, Primitive | 5 | 2023 | 52 | 0.850 |
Why?
|
| Malnutrition | 2 | 2023 | 196 | 0.850 |
Why?
|
| Retrospective Studies | 39 | 2024 | 16021 | 0.830 |
Why?
|
| Histamine Antagonists | 2 | 2013 | 17 | 0.820 |
Why?
|
| Gene-Environment Interaction | 3 | 2015 | 120 | 0.820 |
Why?
|
| Warts | 2 | 2012 | 11 | 0.820 |
Why?
|
| Infant, Newborn | 35 | 2025 | 8108 | 0.820 |
Why?
|
| Asparaginase | 1 | 2022 | 41 | 0.810 |
Why?
|
| Bacteremia | 2 | 2023 | 405 | 0.810 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2024 | 29 | 0.800 |
Why?
|
| Aged | 33 | 2025 | 19080 | 0.790 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2024 | 48 | 0.780 |
Why?
|
| Age Factors | 15 | 2021 | 2802 | 0.780 |
Why?
|
| Hazardous Substances | 1 | 2021 | 17 | 0.770 |
Why?
|
| Anemia | 2 | 2023 | 340 | 0.770 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2012 | 71 | 0.750 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.750 |
Why?
|
| Logistic Models | 17 | 2023 | 1793 | 0.740 |
Why?
|
| Smoking | 4 | 2024 | 1031 | 0.740 |
Why?
|
| Papanicolaou Test | 4 | 2021 | 34 | 0.730 |
Why?
|
| Pancreatitis | 1 | 2022 | 129 | 0.730 |
Why?
|
| Osteomyelitis | 1 | 2023 | 204 | 0.730 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 304 | 0.730 |
Why?
|
| United States | 27 | 2025 | 10631 | 0.700 |
Why?
|
| Odds Ratio | 14 | 2024 | 1243 | 0.690 |
Why?
|
| Premature Birth | 3 | 2021 | 380 | 0.690 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 123 | 0.690 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 224 | 0.690 |
Why?
|
| Fatigue | 9 | 2023 | 216 | 0.680 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 194 | 0.680 |
Why?
|
| Benzene | 4 | 2023 | 24 | 0.680 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 1661 | 0.650 |
Why?
|
| Emigrants and Immigrants | 3 | 2021 | 147 | 0.650 |
Why?
|
| Elastin | 1 | 2019 | 32 | 0.650 |
Why?
|
| Cisplatin | 2 | 2017 | 242 | 0.640 |
Why?
|
| Cytomegalovirus Infections | 3 | 2013 | 217 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 162 | 0.630 |
Why?
|
| Virus Integration | 3 | 2017 | 42 | 0.620 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 227 | 0.620 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 55 | 0.610 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2018 | 23 | 0.600 |
Why?
|
| Autoimmunity | 1 | 2019 | 172 | 0.600 |
Why?
|
| Models, Genetic | 5 | 2014 | 766 | 0.590 |
Why?
|
| F2-Isoprostanes | 3 | 2023 | 23 | 0.570 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 184 | 0.570 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.570 |
Why?
|
| Haplotypes | 5 | 2013 | 519 | 0.560 |
Why?
|
| Life Style | 1 | 2019 | 402 | 0.550 |
Why?
|
| Cohort Studies | 14 | 2025 | 4706 | 0.550 |
Why?
|
| Medical Oncology | 5 | 2024 | 214 | 0.550 |
Why?
|
| Family Health | 3 | 2013 | 259 | 0.550 |
Why?
|
| Proportional Hazards Models | 11 | 2024 | 1305 | 0.540 |
Why?
|
| Neuroblastoma | 4 | 2023 | 509 | 0.540 |
Why?
|
| Specimen Handling | 3 | 2020 | 141 | 0.540 |
Why?
|
| Hypertension | 1 | 2025 | 1287 | 0.530 |
Why?
|
| Oxidative Stress | 6 | 2021 | 796 | 0.530 |
Why?
|
| Survival Rate | 9 | 2025 | 1996 | 0.530 |
Why?
|
| Health Promotion | 1 | 2019 | 390 | 0.520 |
Why?
|
| Autoantibodies | 1 | 2019 | 424 | 0.520 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 474 | 0.520 |
Why?
|
| Sarcoma | 2 | 2019 | 194 | 0.510 |
Why?
|
| Anus Neoplasms | 2 | 2013 | 38 | 0.510 |
Why?
|
| Genetic Association Studies | 5 | 2017 | 761 | 0.510 |
Why?
|
| Superoxide Dismutase | 2 | 2015 | 140 | 0.510 |
Why?
|
| Ear Diseases | 1 | 2015 | 18 | 0.510 |
Why?
|
| Early Detection of Cancer | 7 | 2024 | 349 | 0.500 |
Why?
|
| Cytomegalovirus | 4 | 2015 | 268 | 0.500 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 267 | 0.490 |
Why?
|
| Self Care | 2 | 2023 | 212 | 0.490 |
Why?
|
| Follow-Up Studies | 16 | 2024 | 5047 | 0.490 |
Why?
|
| Viral Load | 2 | 2018 | 383 | 0.480 |
Why?
|
| Cognition Disorders | 2 | 2016 | 555 | 0.470 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 372 | 0.470 |
Why?
|
| Bayes Theorem | 3 | 2023 | 278 | 0.460 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 379 | 0.460 |
Why?
|
| Herpesvirus 8, Human | 4 | 2023 | 49 | 0.460 |
Why?
|
| Sex Factors | 6 | 2021 | 1259 | 0.450 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2013 | 20 | 0.450 |
Why?
|
| Atlases as Topic | 1 | 2014 | 16 | 0.450 |
Why?
|
| Hypospadias | 3 | 2020 | 81 | 0.450 |
Why?
|
| Newspapers as Topic | 1 | 2013 | 6 | 0.450 |
Why?
|
| Biomarkers | 9 | 2023 | 2946 | 0.450 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 15 | 0.450 |
Why?
|
| Journalism, Medical | 1 | 2013 | 9 | 0.450 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2013 | 21 | 0.450 |
Why?
|
| Mexican Americans | 1 | 2015 | 204 | 0.440 |
Why?
|
| RNA, Viral | 3 | 2025 | 541 | 0.440 |
Why?
|
| Meningococcal Vaccines | 1 | 2013 | 30 | 0.440 |
Why?
|
| Genetic Markers | 4 | 2025 | 609 | 0.440 |
Why?
|
| Neurilemmoma | 1 | 2014 | 46 | 0.440 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 1584 | 0.440 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 313 | 0.440 |
Why?
|
| Birth Weight | 6 | 2023 | 336 | 0.430 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2014 | 67 | 0.430 |
Why?
|
| Glutathione Transferase | 2 | 2013 | 153 | 0.430 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 229 | 0.430 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 53 | 0.420 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 43 | 0.420 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2022 | 162 | 0.420 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 2 | 2023 | 37 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 596 | 0.420 |
Why?
|
| Risk-Taking | 1 | 2013 | 92 | 0.420 |
Why?
|
| Mutism | 2 | 2024 | 29 | 0.420 |
Why?
|
| Overweight | 3 | 2022 | 357 | 0.420 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 220 | 0.420 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 159 | 0.410 |
Why?
|
| Risk Assessment | 8 | 2018 | 3316 | 0.410 |
Why?
|
| Encephalitis, Viral | 1 | 2012 | 22 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1227 | 0.410 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 607 | 0.410 |
Why?
|
| Internet | 2 | 2022 | 378 | 0.400 |
Why?
|
| RNA, Messenger | 4 | 2025 | 2813 | 0.400 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 3378 | 0.400 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2012 | 9 | 0.400 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2012 | 47 | 0.400 |
Why?
|
| Air Pollutants, Occupational | 1 | 2012 | 18 | 0.400 |
Why?
|
| Survivors | 8 | 2023 | 345 | 0.400 |
Why?
|
| Herpesviridae Infections | 2 | 2018 | 142 | 0.400 |
Why?
|
| Antifungal Agents | 3 | 2024 | 293 | 0.390 |
Why?
|
| Chromosomes, Human | 1 | 2012 | 131 | 0.390 |
Why?
|
| Hepatoblastoma | 3 | 2024 | 178 | 0.390 |
Why?
|
| Obesity | 5 | 2020 | 2227 | 0.390 |
Why?
|
| Anal Canal | 1 | 2012 | 79 | 0.380 |
Why?
|
| Infant Formula | 3 | 2024 | 98 | 0.380 |
Why?
|
| Supratentorial Neoplasms | 1 | 2011 | 37 | 0.380 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1515 | 0.370 |
Why?
|
| Air Pollution | 3 | 2024 | 67 | 0.370 |
Why?
|
| Maternal Exposure | 4 | 2020 | 148 | 0.370 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 41 | 0.370 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 662 | 0.370 |
Why?
|
| Genetic Linkage | 1 | 2012 | 454 | 0.370 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 70 | 0.360 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 1135 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2016 | 1005 | 0.350 |
Why?
|
| Sleep Wake Disorders | 4 | 2021 | 173 | 0.350 |
Why?
|
| Chromosome Aberrations | 2 | 2017 | 614 | 0.350 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 151 | 0.350 |
Why?
|
| Genome, Human | 2 | 2020 | 1267 | 0.340 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 267 | 0.340 |
Why?
|
| Osteosarcoma | 2 | 2023 | 257 | 0.340 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 770 | 0.340 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 286 | 0.340 |
Why?
|
| Kidney Neoplasms | 2 | 2025 | 432 | 0.330 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 667 | 0.330 |
Why?
|
| Prospective Studies | 10 | 2024 | 6033 | 0.330 |
Why?
|
| Malawi | 6 | 2023 | 389 | 0.330 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 6371 | 0.320 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2008 | 9 | 0.320 |
Why?
|
| Oncology Nursing | 3 | 2020 | 29 | 0.320 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 867 | 0.320 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 1308 | 0.310 |
Why?
|
| Syndrome | 6 | 2022 | 1115 | 0.310 |
Why?
|
| Interleukin-4 | 1 | 2008 | 138 | 0.310 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 12 | 0.310 |
Why?
|
| Neuropsychological Tests | 7 | 2024 | 923 | 0.310 |
Why?
|
| Interleukin-13 | 1 | 2008 | 96 | 0.300 |
Why?
|
| Cranial Irradiation | 3 | 2020 | 69 | 0.300 |
Why?
|
| Thrombosis | 2 | 2025 | 520 | 0.300 |
Why?
|
| Metabolome | 2 | 2021 | 292 | 0.300 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 427 | 0.300 |
Why?
|
| Electronic Health Records | 3 | 2024 | 705 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1117 | 0.300 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 293 | 0.300 |
Why?
|
| Pregnancy | 12 | 2024 | 7148 | 0.300 |
Why?
|
| Pilot Projects | 5 | 2019 | 1388 | 0.300 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 255 | 0.290 |
Why?
|
| Cesarean Section | 3 | 2023 | 382 | 0.290 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2021 | 245 | 0.290 |
Why?
|
| Asthma | 3 | 2013 | 745 | 0.290 |
Why?
|
| Ploidies | 1 | 2007 | 37 | 0.290 |
Why?
|
| Vaginal Douching | 2 | 2018 | 2 | 0.290 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 71 | 0.290 |
Why?
|
| Sex Workers | 2 | 2018 | 5 | 0.290 |
Why?
|
| Exome | 3 | 2017 | 1041 | 0.290 |
Why?
|
| Pain | 5 | 2022 | 470 | 0.280 |
Why?
|
| Gammaherpesvirinae | 1 | 2007 | 5 | 0.280 |
Why?
|
| Creatinine | 3 | 2023 | 380 | 0.280 |
Why?
|
| International Cooperation | 2 | 2018 | 160 | 0.270 |
Why?
|
| Cognition | 3 | 2021 | 735 | 0.260 |
Why?
|
| Sweden | 4 | 2019 | 34 | 0.260 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.260 |
Why?
|
| Unsafe Sex | 2 | 2017 | 20 | 0.260 |
Why?
|
| Sarcoma, Ewing | 2 | 2024 | 113 | 0.250 |
Why?
|
| Pediatrics | 4 | 2021 | 1139 | 0.250 |
Why?
|
| DNA-Binding Proteins | 4 | 2019 | 2047 | 0.250 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 228 | 0.250 |
Why?
|
| Mass Screening | 5 | 2023 | 788 | 0.250 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2005 | 56 | 0.250 |
Why?
|
| Survival Analysis | 3 | 2021 | 1472 | 0.250 |
Why?
|
| Parents | 4 | 2023 | 1030 | 0.250 |
Why?
|
| DNA Repair | 4 | 2021 | 579 | 0.240 |
Why?
|
| Fluorometry | 1 | 2025 | 27 | 0.240 |
Why?
|
| Carcinoma | 1 | 2007 | 278 | 0.240 |
Why?
|
| Epigenesis, Genetic | 3 | 2025 | 665 | 0.240 |
Why?
|
| Bevacizumab | 1 | 2025 | 63 | 0.240 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 221 | 0.240 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.240 |
Why?
|
| Feasibility Studies | 2 | 2019 | 751 | 0.240 |
Why?
|
| Candida tropicalis | 1 | 2024 | 16 | 0.240 |
Why?
|
| Antisickling Agents | 1 | 2024 | 17 | 0.240 |
Why?
|
| Minority Groups | 3 | 2023 | 252 | 0.230 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 19 | 0.230 |
Why?
|
| Pedigree | 3 | 2013 | 1584 | 0.230 |
Why?
|
| Anticoagulants | 2 | 2021 | 581 | 0.230 |
Why?
|
| Gestational Age | 4 | 2023 | 1136 | 0.230 |
Why?
|
| Splenic Diseases | 1 | 2024 | 28 | 0.230 |
Why?
|
| Colorectal Neoplasms | 2 | 2025 | 560 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 96 | 0.230 |
Why?
|
| Astrocytoma | 2 | 2023 | 103 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1682 | 0.230 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2024 | 49 | 0.230 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2024 | 49 | 0.230 |
Why?
|
| Splenomegaly | 1 | 2024 | 34 | 0.230 |
Why?
|
| Splenectomy | 1 | 2024 | 60 | 0.230 |
Why?
|
| Risk | 6 | 2019 | 747 | 0.230 |
Why?
|
| Lymphopenia | 1 | 2024 | 36 | 0.230 |
Why?
|
| Quality of Life | 4 | 2023 | 1929 | 0.230 |
Why?
|
| Chromatin | 1 | 2007 | 552 | 0.230 |
Why?
|
| Hearing Loss | 2 | 2017 | 131 | 0.230 |
Why?
|
| Poverty Areas | 2 | 2021 | 30 | 0.220 |
Why?
|
| Nucleic Acids | 1 | 2023 | 23 | 0.220 |
Why?
|
| Patient Selection | 1 | 2007 | 685 | 0.220 |
Why?
|
| Wilms Tumor | 1 | 2025 | 111 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2023 | 470 | 0.220 |
Why?
|
| Social Class | 2 | 2020 | 192 | 0.220 |
Why?
|
| Severe Acute Malnutrition | 1 | 2023 | 21 | 0.220 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 195 | 0.220 |
Why?
|
| DNA End-Joining Repair | 1 | 2023 | 34 | 0.220 |
Why?
|
| Vaginal Smears | 4 | 2023 | 51 | 0.210 |
Why?
|
| Leuprolide | 1 | 2023 | 25 | 0.210 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 11 | 0.210 |
Why?
|
| Acute Disease | 2 | 2023 | 1094 | 0.210 |
Why?
|
| Intelligence | 1 | 2023 | 98 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 247 | 0.210 |
Why?
|
| Antioxidants | 2 | 2018 | 338 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1309 | 0.210 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 801 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 2394 | 0.210 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 121 | 0.210 |
Why?
|
| Body Mass Index | 4 | 2020 | 1541 | 0.210 |
Why?
|
| Immunoglobulins | 1 | 2023 | 169 | 0.210 |
Why?
|
| Mucositis | 1 | 2022 | 18 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2023 | 51 | 0.200 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 233 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.200 |
Why?
|
| Lod Score | 2 | 2012 | 120 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 140 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 136 | 0.200 |
Why?
|
| Immediate-Early Proteins | 2 | 2015 | 58 | 0.200 |
Why?
|
| Monocytes | 2 | 2023 | 346 | 0.200 |
Why?
|
| Enterobacter | 1 | 2021 | 14 | 0.190 |
Why?
|
| Maternal Age | 2 | 2022 | 137 | 0.190 |
Why?
|
| Mothers | 2 | 2023 | 350 | 0.190 |
Why?
|
| Biliary Atresia | 1 | 2024 | 186 | 0.190 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2012 | 87 | 0.190 |
Why?
|
| Lymphoma | 2 | 2015 | 321 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2022 | 48 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2022 | 62 | 0.190 |
Why?
|
| Congresses as Topic | 3 | 2018 | 170 | 0.190 |
Why?
|
| Milk, Human | 1 | 2024 | 300 | 0.190 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 5 | 0.190 |
Why?
|
| Demography | 1 | 2022 | 239 | 0.190 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 75 | 0.190 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 9 | 0.190 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 29 | 0.190 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 55 | 0.190 |
Why?
|
| Maltose | 1 | 2021 | 16 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2016 | 651 | 0.190 |
Why?
|
| Neurocognitive Disorders | 1 | 2021 | 67 | 0.190 |
Why?
|
| Interferon Type I | 2 | 2013 | 107 | 0.190 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 52 | 0.190 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2021 | 5 | 0.190 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 41 | 0.190 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 42 | 0.190 |
Why?
|
| Causality | 1 | 2021 | 83 | 0.190 |
Why?
|
| Rhinitis | 1 | 2021 | 38 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 105 | 0.180 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 217 | 0.180 |
Why?
|
| Ferric Compounds | 1 | 2021 | 37 | 0.180 |
Why?
|
| Phosphorus | 1 | 2021 | 55 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 232 | 0.180 |
Why?
|
| Drug Hypersensitivity | 1 | 2022 | 96 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 173 | 0.180 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 459 | 0.180 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.180 |
Why?
|
| Paternal Exposure | 1 | 2020 | 10 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2021 | 89 | 0.180 |
Why?
|
| Weight Gain | 2 | 2023 | 401 | 0.180 |
Why?
|
| Repressor Proteins | 1 | 2005 | 810 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 169 | 0.180 |
Why?
|
| Europe | 2 | 2021 | 374 | 0.170 |
Why?
|
| Mycoses | 1 | 2021 | 117 | 0.170 |
Why?
|
| Neonatal Screening | 2 | 2020 | 184 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2019 | 393 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 297 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 22 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2021 | 123 | 0.170 |
Why?
|
| Recurrence | 2 | 2021 | 1422 | 0.170 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 2106 | 0.170 |
Why?
|
| Medically Underserved Area | 2 | 2023 | 92 | 0.170 |
Why?
|
| Software | 1 | 2024 | 677 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 211 | 0.170 |
Why?
|
| Exercise | 3 | 2023 | 808 | 0.170 |
Why?
|
| Canada | 2 | 2017 | 296 | 0.170 |
Why?
|
| Radiation Exposure | 1 | 2020 | 43 | 0.170 |
Why?
|
| Bone Marrow | 1 | 2021 | 323 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2025 | 312 | 0.170 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2019 | 12 | 0.160 |
Why?
|
| Leukocyte Elastase | 1 | 2019 | 19 | 0.160 |
Why?
|
| Vincristine | 2 | 2017 | 195 | 0.160 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2020 | 108 | 0.160 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 68 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 418 | 0.160 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 1213 | 0.160 |
Why?
|
| Colposcopy | 3 | 2021 | 14 | 0.160 |
Why?
|
| Child Development | 1 | 2021 | 261 | 0.160 |
Why?
|
| Retinal Neoplasms | 1 | 2020 | 98 | 0.160 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 170 | 0.160 |
Why?
|
| Vital Capacity | 1 | 2019 | 76 | 0.160 |
Why?
|
| Disease Progression | 4 | 2024 | 2025 | 0.160 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 249 | 0.160 |
Why?
|
| Chromosome Mapping | 2 | 2012 | 1081 | 0.160 |
Why?
|
| Smokers | 1 | 2019 | 39 | 0.160 |
Why?
|
| Butadienes | 2 | 2015 | 19 | 0.160 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 326 | 0.160 |
Why?
|
| Reproductive Tract Infections | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 617 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 174 | 0.160 |
Why?
|
| Research | 2 | 2022 | 263 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 133 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 137 | 0.150 |
Why?
|
| Nitrosative Stress | 1 | 2018 | 2 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 159 | 0.150 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 169 | 0.150 |
Why?
|
| Paternal Age | 1 | 2018 | 13 | 0.150 |
Why?
|
| Gene Frequency | 3 | 2019 | 713 | 0.150 |
Why?
|
| Caregivers | 1 | 2023 | 572 | 0.150 |
Why?
|
| Optic Nerve Glioma | 1 | 2018 | 21 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 113 | 0.150 |
Why?
|
| Phosphoproteins | 2 | 2021 | 399 | 0.150 |
Why?
|
| Nausea | 4 | 2020 | 97 | 0.150 |
Why?
|
| Tyrosine | 1 | 2018 | 152 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 351 | 0.150 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 233 | 0.150 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 823 | 0.150 |
Why?
|
| Age of Onset | 2 | 2025 | 581 | 0.140 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 32 | 0.140 |
Why?
|
| Germ Cells | 3 | 2024 | 192 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 230 | 0.140 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 41 | 0.140 |
Why?
|
| Proteomics | 1 | 2021 | 479 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1386 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 1582 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2015 | 1529 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 477 | 0.140 |
Why?
|
| Algorithms | 3 | 2021 | 1592 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 224 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2017 | 42 | 0.140 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 17 | 0.140 |
Why?
|
| Down Syndrome | 1 | 2019 | 195 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 107 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 88 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 59 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 21 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2019 | 510 | 0.140 |
Why?
|
| Alleles | 3 | 2017 | 1603 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 644 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2012 | 518 | 0.140 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 64 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 530 | 0.130 |
Why?
|
| Depression | 2 | 2022 | 1217 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 609 | 0.130 |
Why?
|
| Calreticulin | 1 | 2016 | 19 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 420 | 0.130 |
Why?
|
| Oropharynx | 1 | 2016 | 33 | 0.130 |
Why?
|
| Thrombopoietin | 1 | 2016 | 30 | 0.130 |
Why?
|
| Chickenpox | 1 | 2016 | 20 | 0.130 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2016 | 31 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2016 | 15 | 0.130 |
Why?
|
| Interviews as Topic | 3 | 2018 | 368 | 0.130 |
Why?
|
| Sex Work | 1 | 2016 | 3 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 127 | 0.130 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 28 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 143 | 0.130 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1042 | 0.130 |
Why?
|
| Denmark | 2 | 2013 | 32 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 179 | 0.130 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1068 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 1198 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 33 | 0.130 |
Why?
|
| Radon | 1 | 2015 | 11 | 0.130 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 809 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 935 | 0.130 |
Why?
|
| Population Dynamics | 1 | 2015 | 29 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 467 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 300 | 0.130 |
Why?
|
| Self-Examination | 1 | 2015 | 7 | 0.130 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2012 | 25 | 0.120 |
Why?
|
| Inflammation | 3 | 2013 | 1401 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2015 | 30 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 156 | 0.120 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3013 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 109 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2019 | 747 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 715 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 136 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 699 | 0.120 |
Why?
|
| Alphapapillomavirus | 2 | 2012 | 30 | 0.120 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 5 | 0.120 |
Why?
|
| San Francisco | 2 | 2013 | 17 | 0.120 |
Why?
|
| Regression Analysis | 3 | 2011 | 771 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 813 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 22 | 0.120 |
Why?
|
| DNA | 1 | 2020 | 1592 | 0.120 |
Why?
|
| Antigens, Viral | 2 | 2016 | 435 | 0.120 |
Why?
|
| Cities | 1 | 2014 | 48 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 861 | 0.110 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Search Engine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Vaccination | 2 | 2016 | 951 | 0.110 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2025 | 66 | 0.110 |
Why?
|
| Spectrum Analysis | 2 | 2011 | 61 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 154 | 0.110 |
Why?
|
| Affective Symptoms | 1 | 2014 | 60 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 83 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 158 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1285 | 0.110 |
Why?
|
| Eating | 1 | 2016 | 372 | 0.110 |
Why?
|
| Mass Media | 1 | 2013 | 28 | 0.110 |
Why?
|
| Bibliometrics | 1 | 2013 | 29 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 3666 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 518 | 0.110 |
Why?
|
| Emigration and Immigration | 1 | 2014 | 81 | 0.110 |
Why?
|
| Infant Food | 1 | 2013 | 81 | 0.110 |
Why?
|
| Urticaria | 1 | 2013 | 20 | 0.110 |
Why?
|
| Eczema | 1 | 2013 | 28 | 0.110 |
Why?
|
| DNA Ligases | 2 | 2010 | 16 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12129 | 0.110 |
Why?
|
| Allergy and Immunology | 1 | 2013 | 25 | 0.110 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 29 | 0.110 |
Why?
|
| Xenobiotics | 1 | 2013 | 27 | 0.110 |
Why?
|
| Survivorship | 2 | 2023 | 36 | 0.110 |
Why?
|
| Israel | 1 | 2013 | 44 | 0.110 |
Why?
|
| Urban Population | 1 | 2014 | 221 | 0.110 |
Why?
|
| Electronics | 2 | 2023 | 43 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2012 | 29 | 0.100 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 80 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 46 | 0.100 |
Why?
|
| Proteins | 1 | 2018 | 1037 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2012 | 112 | 0.100 |
Why?
|
| Time Factors | 4 | 2016 | 6217 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2838 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2012 | 10 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2012 | 14 | 0.100 |
Why?
|
| Psychometrics | 1 | 2016 | 657 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 332 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 210 | 0.100 |
Why?
|
| Tanzania | 2 | 2023 | 68 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 165 | 0.100 |
Why?
|
| Solvents | 1 | 2012 | 42 | 0.100 |
Why?
|
| Biopsy | 2 | 2024 | 1237 | 0.100 |
Why?
|
| Biomedical Technology | 1 | 2012 | 35 | 0.100 |
Why?
|
| Melanoma | 1 | 2019 | 824 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 135 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 669 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 795 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 481 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 603 | 0.090 |
Why?
|
| Professional Competence | 1 | 2012 | 97 | 0.090 |
Why?
|
| In Situ Hybridization | 2 | 2012 | 473 | 0.090 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2011 | 11 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 176 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 123 | 0.090 |
Why?
|
| Breast Feeding | 2 | 2023 | 221 | 0.090 |
Why?
|
| Poliovirus Vaccines | 1 | 2011 | 14 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 24 | 0.090 |
Why?
|
| Haemophilus Vaccines | 1 | 2011 | 30 | 0.090 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 70 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2019 | 2585 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 310 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 171 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 56 | 0.090 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 41 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 659 | 0.090 |
Why?
|
| Birth Order | 1 | 2010 | 7 | 0.090 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 10 | 0.090 |
Why?
|
| HMGA2 Protein | 1 | 2010 | 10 | 0.090 |
Why?
|
| Health Behavior | 1 | 2013 | 381 | 0.090 |
Why?
|
| Body Height | 2 | 2017 | 210 | 0.090 |
Why?
|
| Phenotype | 4 | 2023 | 4228 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 472 | 0.080 |
Why?
|
| Censuses | 2 | 2022 | 11 | 0.080 |
Why?
|
| Platelet Count | 2 | 2022 | 133 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 86 | 0.080 |
Why?
|
| Siblings | 1 | 2010 | 195 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 99 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 124 | 0.080 |
Why?
|
| DNA Helicases | 1 | 2010 | 224 | 0.080 |
Why?
|
| Mutation | 4 | 2025 | 5773 | 0.080 |
Why?
|
| Mexico | 2 | 2021 | 179 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1687 | 0.080 |
Why?
|
| Neutropenia | 1 | 2009 | 202 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1168 | 0.070 |
Why?
|
| Image Cytometry | 1 | 2007 | 13 | 0.070 |
Why?
|
| ROC Curve | 3 | 2019 | 556 | 0.070 |
Why?
|
| Cambodia | 2 | 2018 | 11 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 321 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 537 | 0.070 |
Why?
|
| Body Weight | 2 | 2017 | 1001 | 0.070 |
Why?
|
| Computational Biology | 2 | 2021 | 798 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 400 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1870 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 803 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 136 | 0.070 |
Why?
|
| Nervous System | 1 | 2007 | 128 | 0.070 |
Why?
|
| Vaccines | 1 | 2011 | 370 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 809 | 0.060 |
Why?
|
| International Agencies | 2 | 2018 | 28 | 0.060 |
Why?
|
| Transcriptome | 2 | 2021 | 905 | 0.060 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 22 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1262 | 0.060 |
Why?
|
| Limit of Detection | 1 | 2025 | 60 | 0.060 |
Why?
|
| Medical History Taking | 2 | 2019 | 106 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1239 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2012 | 821 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 12 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 137 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2010 | 1019 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 25 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1292 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 183 | 0.060 |
Why?
|
| Insecticides | 1 | 2023 | 39 | 0.060 |
Why?
|
| HIV-1 | 2 | 2018 | 465 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 84 | 0.050 |
Why?
|
| Uganda | 1 | 2023 | 70 | 0.050 |
Why?
|
| Extremities | 1 | 2023 | 82 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 56 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 1677 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 53 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 37 | 0.050 |
Why?
|
| Patient Preference | 1 | 2023 | 116 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2005 | 325 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 142 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Philadelphia | 1 | 2022 | 25 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 586 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 512 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 253 | 0.050 |
Why?
|
| Computers | 1 | 2021 | 67 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 797 | 0.050 |
Why?
|
| Protons | 1 | 2021 | 91 | 0.050 |
Why?
|
| Emotions | 1 | 2024 | 359 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 120 | 0.050 |
Why?
|
| Penicillins | 1 | 2022 | 154 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 185 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2021 | 150 | 0.050 |
Why?
|
| Phosphotransferases | 1 | 2021 | 41 | 0.050 |
Why?
|
| Executive Function | 1 | 2021 | 106 | 0.050 |
Why?
|
| Telomerase | 1 | 2021 | 161 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 419 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 352 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 100 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 354 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2023 | 451 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 603 | 0.040 |
Why?
|
| DNA Ligase ATP | 2 | 2010 | 11 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 28 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 39 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 54 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 672 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 58 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 101 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 191 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2023 | 847 | 0.040 |
Why?
|
| Angola | 1 | 2018 | 5 | 0.040 |
Why?
|
| Fetal Development | 1 | 2020 | 111 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 58 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 345 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 779 | 0.040 |
Why?
|
| Botswana | 1 | 2018 | 76 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 233 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 459 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 247 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 101 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 375 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1009 | 0.040 |
Why?
|
| Hematology | 1 | 2018 | 38 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.040 |
Why?
|
| Cross Infection | 1 | 2021 | 331 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 382 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1088 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2017 | 4 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 62 | 0.040 |
Why?
|
| Washington | 1 | 2017 | 33 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 995 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 268 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 577 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 143 | 0.040 |
Why?
|
| Animals | 4 | 2020 | 33749 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 37 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 401 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 4346 | 0.030 |
Why?
|
| Paper | 1 | 2016 | 6 | 0.030 |
Why?
|
| Collodion | 1 | 2016 | 8 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 658 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2830 | 0.030 |
Why?
|
| Spain | 1 | 2016 | 53 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1337 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 372 | 0.030 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2016 | 7 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 10 | 0.030 |
Why?
|
| Greece | 1 | 2016 | 11 | 0.030 |
Why?
|
| Egypt | 1 | 2016 | 23 | 0.030 |
Why?
|
| New Zealand | 1 | 2016 | 50 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 9 | 0.030 |
Why?
|
| France | 1 | 2016 | 78 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 112 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 84 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2016 | 121 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1726 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 48 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 150 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 40 | 0.030 |
Why?
|
| Inhalation Exposure | 1 | 2015 | 36 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 752 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 34 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 300 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 59 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 449 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 22 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 92 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1683 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 697 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2025 | 0.030 |
Why?
|
| Family | 1 | 2017 | 579 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 410 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1496 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 1100 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 314 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 386 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 115 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2014 | 123 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2012 | 4 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 243 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1478 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 659 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2013 | 98 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1339 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 333 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 609 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3273 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 519 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 29 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 32 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2011 | 5 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2525 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 232 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 261 | 0.020 |
Why?
|
| Decision Trees | 1 | 2010 | 49 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 153 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2010 | 54 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 20 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2961 | 0.020 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2009 | 26 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2010 | 78 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 105 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 88 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 601 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1877 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 270 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 12 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 21 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 40 | 0.020 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 26 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 43 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 56 | 0.020 |
Why?
|
| Endonucleases | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cell Phone | 1 | 2008 | 29 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 993 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 303 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 216 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 653 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1781 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 695 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2010 | 403 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 501 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1863 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1414 | 0.020 |
Why?
|
| Mice | 2 | 2013 | 17494 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2388 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4271 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4489 | 0.010 |
Why?
|